Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00056459 | Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer. | PHASE3 | COMPLETED | 1,168 | — | — | Feb 1, 2003 | - | Feb 10, 2020 | 223 | United States, Australia +17 |
| NCT00056446 | Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer | PHASE3 | COMPLETED | 855 | — | — | Jan 1, 2003 | Jan 1, 2007 | Mar 6, 2017 | 251 | United States, Australia +16 |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Oxaliplatin/5-FU/LV and PTK787/ZK 222584 |
| 2 | PLACEBO_COMPARATOR | Oxaliplatin/5-FU/LV and placebo |
| Name | Type | Description |
|---|---|---|
| Vatalanib | DRUG | - |
Inclusion criteria: * Patients with metastatic colorectal cancer coming for initial chemotherapy * Documented metastatic colorectal cancer * WHO Performance Status of 0, 1, or 2 * Measurable tumors * Adequate hematologic status, liver and kidney function * Life expectancy greater than 12 weeks * Wr...